Assay News and Research

RSS

Rapid COVID-19 antibody detection with time‐resolved fluorescence immunoassay

A new study published in the journal Biotechnology and Applied Biochemistry deals with the development of a time-resolved fluorescence immunoassay (TRFIA) for the detection of total COVID-19 antibodies in humans.

15 Jul 2021

AMSBIO introduces new range of research grade biosimilars

AMSBIO has launched a new range of research grade biosimilars that enable analysis of biological processes without the need to purchase expensive therapeutic-grade biologics.

From AMS Biotechnology 15 Jul 2021

A pencil graphite biosensor that detects SARS-CoV-2

In a new study, scientists discuss the development of a rapid COVID-19 diagnostic tool known as the Low-cost Electrochemical Advanced Diagnostic (LEAD).

14 Jul 2021

New OMV-based COVID-19 vaccine candidate proves effective in mice

Researchers in Italy have demonstrated the efficacy of using modified outer membrane vesicles (OMVs) as a vaccine to protect against coronavirus disease 2019 (COVID-19) in an animal model.

14 Jul 2021

High individual-level variability in SARS-CoV-2 shedding may explain superspreading

Researchers in the United States have provided a high-resolution description of the viral dynamics involved in acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

14 Jul 2021

Neutralizing aptamers block SARS-CoV-2 infection in vitro

A new study describes the clinical utility of aptamers against SARS-CoV-2.

13 Jul 2021

The progressive increase in transmissibility and virulence of emerging SARS-CoV-2 variants could lead to a significantly more deadly pandemic

Researchers from Toronto University, Canada, recently showed that these emerging VOCs were linked to increased virulence, as determined by hospitalization risk, ICU admission, and mortality. This study is currently available on the medRxiv* preprint server.

12 Jul 2021

SARS-CoV-2 mRNA vaccine efficacy reduced in patients with CD20-B-cell depleting treatment history

Researchers from Switzerland recently investigated humoral and cell-mediated immune responses to mRNA-based vaccines in patients undergoing treatment with CD20-B-cell depleting agents for autoimmune diseases, transplantation, or malignancy.

12 Jul 2021

Pfizer-BioNTech’s COVID-19 vaccine effective and safe for use among cancer patients

Researchers in Israel have conducted a study showing that the use of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine appears to be safe and effective among patients with cancer.

11 Jul 2021

Initial SARS-CoV-2 vaccination response may predict BNT162b2 booster response, but not AZD1222

A new study finds that the antibody titer values prior to the booster dose of the BNT162b2 vaccine can predict the final antibody response after two doses.

11 Jul 2021

Study examines SARS-CoV-2's inactivation across a range of UVC wavelengths

A recent study published on the preprint server medRxiv* describes the disinfection of SARS-CoV-2 using UVC irradiation at different wavelengths.

11 Jul 2021

Scientists analyze the sensitivity of SARS-CoV-2 Delta variant to monoclonal antibodies

The Delta variant was detected for the first time in India in October 2020 and has since spread throughout the world.

9 Jul 2021

SARS-CoV-2 antibody testing in oral fluids may be an efficient way forward for research in children

A recent study by researchers from the United Kingdom (UK) and Brazil shows how laboratory assays based on the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in oral fluids can be used as a suitable tool for population-based seroepidemiology studies in children. The paper is currently available on the medRxiv* preprint server while it undergoes peer review.

8 Jul 2021

Breakthrough SARS-CoV-2 infection among fully vaccinated likely to be less transmissible

Researchers in the United States have conducted a study suggesting that individuals fully vaccinated against coronavirus disease 2019 (COVID-19) who develop breakthrough infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are less likely to transmit the virus to others than unvaccinated infected individuals.

8 Jul 2021

Scientists discover drug candidates for treating liver fibrosis among pesticides

Skoltech biologists and their colleagues from Koltzov Institute of Developmental Biology, Russia, and the Chemistry Department of Taras Shevchenko University in Ukraine have discovered fairly unlikely drug candidates for treating liver fibrosis and other pathologies -- among pest control chemicals.

8 Jul 2021

Striking increase in SARS-CoV-2 antibodies seen with prime dose AstraZeneca vaccine followed by Pfizer-BioNTech

Researchers in Germany have provided evidence that a booster shot of a messenger RNA (mRNA)-based coronavirus disease 2019 (COVID-19) vaccine following prime immunization with AstraZeneca’s adenoviral vector-based vaccine is sufficient to achieve high levels of neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Jul 2021

New study reports low SARS-CoV-2 breakthrough infections in vaccinated healthcare workers

Researchers examined cases of SARS-CoV-2 infection in fully and partially vaccinated healthcare workers, finding that vaccination provided strong immunity to the virus even though VOCs are on the rise in the non-vaccinated community at large.

7 Jul 2021

University of Liverpool signs option agreement with BARD1 for type 3C diabetes test

The University of Liverpool has signed a two year option agreement with the Australian diagnostics company, BARD1 Life Sciences Ltd (ASX: BD1), for a type 3c diabetes (T3cDM) blood test. The test uses patented technology developed by researchers in the University of Liverpool's Institute of Systems, Molecular and Integrative Biology.

7 Jul 2021

Study shows antibody titers after natural SARS-CoV-2 infection last longer than previously thought

A recent study by researchers from the United Kingdom (UK) revealed that antibody levels associated with protection against reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are likely to last from 1.5 to 2 years on average and that the protection from severe infection may be present for several years.

7 Jul 2021

Study examines evolution and avidity of anti-SARS-CoV-2 IgG antibodies after mRNA vaccination

New research released on the medRxiv* preprint server has measured antibody responses in 71 mRNA vaccinated adults (54 vaccinated with Pfizer and 17 vaccinated with Moderna).

6 Jul 2021

Assay News and Research

Rapid COVID-19 antibody detection with time‐resolved fluorescence immunoassay

AMSBIO introduces new range of research grade biosimilars

A pencil graphite biosensor that detects SARS-CoV-2

New OMV-based COVID-19 vaccine candidate proves effective in mice

High individual-level variability in SARS-CoV-2 shedding may explain superspreading

Neutralizing aptamers block SARS-CoV-2 infection in vitro

The progressive increase in transmissibility and virulence of emerging SARS-CoV-2 variants could lead to a significantly more deadly pandemic

SARS-CoV-2 mRNA vaccine efficacy reduced in patients with CD20-B-cell depleting treatment history

Pfizer-BioNTech’s COVID-19 vaccine effective and safe for use among cancer patients

Initial SARS-CoV-2 vaccination response may predict BNT162b2 booster response, but not AZD1222

Study examines SARS-CoV-2's inactivation across a range of UVC wavelengths

Scientists analyze the sensitivity of SARS-CoV-2 Delta variant to monoclonal antibodies

SARS-CoV-2 antibody testing in oral fluids may be an efficient way forward for research in children

Breakthrough SARS-CoV-2 infection among fully vaccinated likely to be less transmissible

Scientists discover drug candidates for treating liver fibrosis among pesticides

Striking increase in SARS-CoV-2 antibodies seen with prime dose AstraZeneca vaccine followed by Pfizer-BioNTech

New study reports low SARS-CoV-2 breakthrough infections in vaccinated healthcare workers

University of Liverpool signs option agreement with BARD1 for type 3C diabetes test

Study shows antibody titers after natural SARS-CoV-2 infection last longer than previously thought

Study examines evolution and avidity of anti-SARS-CoV-2 IgG antibodies after mRNA vaccination

eBook: Using iPSCs models for human disease research and drug discovery eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News